½ÃÀ庸°í¼­
»óǰÄÚµå
1553464

Çö󽺹̵å Á¤Á¦ ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : Á¦Ç° ¹× ¼­ºñ½ºº°, µî±Þº°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2024-2030³â)

Plasmid Purification Market Size, Share & Trends Analysis Report By Product & Service (Kits & Reagents, Instruments), By Grade (Molecular Grade, Transfection Grade), By Application, By End-use, By Region, And Segment Forecasts, 2024 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 120 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Çö󽺹̵å Á¤Á¦ ½ÃÀå ¼ºÀå°ú µ¿Çâ:

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é, ¼¼°è Çö󽺹̵å Á¤Á¦ ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 36¾ï 9,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2024³âºÎÅÍ 2030³â±îÁö ¿¬Æò±Õ 11.60%ÀÇ ¼ºÀå·üÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·áÀÇ ¼ö¿ë È®´ë¿Í ÀçÁ¶ÇÕ ±â¼ú Á¦Ç°¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡°¡ ½ÃÀå ¼ºÀåÀÇ ¿äÀÎÀÔ´Ï´Ù. ¶ÇÇÑ, Çö󽺹̵å Á¤Á¦ ±â¼úÀÇ ¹ßÀüÀº ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇÒ °ÍÀÔ´Ï´Ù.

Çö󽺹̵å´Â À¯ÀüÀÚ Ä¡·á¿Í À¯ÀüÀÚ ÀÇÇп¡¼­ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. µ¶Æ¯ÇÑ Æ¯¼ºÀ¸·Î ÀÎÇØ Ä¡·á¿ë À¯ÀüÀÚ¸¦ Ç¥Àû ¼¼Æ÷¿¡ µµÀÔÇÏ´Â È¿°úÀûÀÎ º¤ÅÍ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Çö󽺹̵å´Â ƯÁ¤ ¼¼Æ÷¿¡ ¿Ü·¡ À¯ÀüÀÚ¸¦ µµÀÔÇÏ¿© Áúº´À» À¯¹ßÇÏ´Â °áÇÔ À¯ÀüÀÚ¸¦ ¼öÁ¤Çϰųª ´ëüÇÏ´Â ¿ªÇÒÀ» ÇÕ´Ï´Ù. ¶ÇÇÑ, ´Ù¾çÇÑ Áúº´ Ä¡·á¸¦ À§ÇØ À¯ÀüÀÚ Ä¡·á°¡ ¼ö¿ëµÇ°í Àû¿ëµÊ¿¡ µû¶ó Á¤Á¦µÈ Çö󽺹̵å DNAÀÇ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. À¯ÀüÀÚ Ä¡·á¿¡¼­ Çö󽺹̵å´Â Ä¡·á À¯ÀüÀÚ¸¦ Àü´ÞÇϱâ À§ÇÑ º¤ÅÍ ¿ªÇÒÀ» ÇÕ´Ï´Ù.

¿¬±¸ÀÚµéÀº µ¹¿¬º¯ÀÌµÈ À¯ÀüÀÚÀÇ Á¤»ó »çº», Áúº´°ú ½Î¿ì´Â ´Ü¹éÁúÀ» ¾ÏȣȭÇÏ´Â À¯ÀüÀÚ, ¶Ç´Â À¯ÇØÇÑ À¯ÀüÀÚ¸¦ ħ¹¬½ÃŰ´Â shRNA¿Í °°Àº RNA ºÐÀÚ µî Ä¡·á¿ë À¯ÀüÀÚ¸¦ ¿î¹ÝÇÏ´Â Çö󽺹̵带 ¼³°èÇÕ´Ï´Ù. Çö󽺹̵åÀÇ Á¤Á¦´Â À¯ÀüÀÚ Ä¡·áÁ¦ÀÇ °³¹ß ¹× Àû¿ë¿¡ ÀÖ¾î ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ¿°»öü DNA, ´Ü¹éÁú, ³»µ¶¼Ò, ÀÜ·ù ¼¼±Õ ¼ººÐ°ú °°Àº ¿À¿° ¹°ÁúÀº Ä¡·á Á¦Ç°ÀÇ È¿´É°ú ¾ÈÀü¼ºÀ» ÀúÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. µû¶ó¼­ Á¤Á¦ ±â¼úÀÇ ¹ßÀüÀº Çö󽺹̵å DNAÀÇ ¼öÀ²°ú ǰÁúÀ» Çâ»ó½Ã۰í ÇÃ¶ó½º¹Ìµå »ý»êÀÇ È®À强À» ÃËÁøÇÒ ¼ö ÀÖ½À´Ï´Ù.

COVID-19 ÆÒµ¥¹ÍÀº ½ÃÀå ¼ºÀå¿¡ Å« ¿µÇâÀ» ¹ÌÄ¡°í ÀÖÀ¸¸ç, COVID-19 ¹é½Å°ú Ä¡·áÁ¦¿¡ ´ëÇÑ ±ä±ÞÇÑ Çʿ伺¿¡ ÈûÀÔ¾î ÇÕ¼º»ý¹°ÇÐ Á¦Ç°¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϸ鼭 º¹Á¦ ±â¼ú ¿¬±¸ °³¹ß(R&D)ÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÇÕ¼º»ý¹°ÇÐ ºÐ¾ßÀÇ R&D Ȱµ¿ÀÇ ±ÞÁõÀº ¹é½Å °³¹ß, Áø´Ü ¹× Ä¡·á ¿¬±¸¿¡ Á¾»çÇÏ´Â ±â¾÷µé¿¡ ´ëÇÑ ÀÚ±Ý Áö¿ø°ú ÅõÀÚ Áõ°¡·Î À̾îÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÆÒµ¥¹ÍÀ¸·Î ÀÎÇÑ µµÀü¿¡µµ ºÒ±¸Çϰí, »õ·Î¿î ±â¼úÀÇ Ã¤Åà Áõ°¡, À¯ÀüÀÚ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, À¯Àü°øÇÐÀÇ Áö¼ÓÀûÀÎ ¹ßÀü µîÀ¸·Î ÀÎÇØ ½ÃÀåÀº ¾ÈÁ¤ÀûÀÎ ¼ºÀå¼¼¸¦ À̾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

±×·¯³ª ÀçÁ¶ÇÕ DNA ±â¼ú »ç¿ë°ú °ü·ÃµÈ À±¸®Àû Á¦¾àÀº À¯ÀüÀÚ º¹Á¦ ¹× ÇÕ¼º ±â¼úÀ» ¾Ç¿ëÇÏ¿© ÇÕ¼º»ý¹°ÇÐ ±â¼úÀ» ÅëÇØ À¯ÇØÇÑ º´¿ø±ÕÀ» ¸¸µé¾î »ý¹°¹«±â¸¦ °³¹ßÇÏ´Â µ¥ ¾Ç¿ëµÉ ¼ö ÀÖ´Ù´Â °ÍÀÌ ½ÃÀåÀÇ ÁÖ¿ä °ü½É»ç Áß ÇϳªÀÔ´Ï´Ù. ÇÕ¼º DNA¿Í Çö󽺹̵åÀÇ ºÎÀûÀýÇÑ Ãë±Þ ¹× Æó±â´Â ȯ°æ ¿À¿°À¸·Î À̾îÁú ¼ö ÀÖ½À´Ï´Ù. ȯ°æ¿¡ ¹æÃâµÈ Àΰø»ý¹°Àº »ýŰ迡 ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù.

Çö󽺹̵å Á¤Á¦ ½ÃÀå º¸°í¼­ - ÇÏÀ̶óÀÌÆ®

  • Àü¿ë ŰƮ ¹× ½Ã¾àÀÇ »ç¿ëÀ¸·Î Á¤Á¦ °øÁ¤ÀÇ È¿À²¼º, ½Å·Ú¼º ¹× ǰÁúÀÌ Å©°Ô Çâ»óµÊ¿¡ µû¶ó Á¦Ç° ºÎ¹®ÀÌ 2023³â 72.93%ÀÇ ÃÖ´ë ¸ÅÃâ Á¡À¯À²·Î ½ÃÀåÀ» ÁÖµµÇß½À´Ï´Ù. ¶ÇÇÑ, ¼­ºñ½º ºÎ¹®Àº 2024³âºÎÅÍ 2030³â±îÁö 12.58%ÀÇ ³ôÀº CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • µî±Þº°·Î´Â ºÐÀÚ µî±Þ ºÎ¹®ÀÌ 2023³â 58.42%ÀÇ °¡Àå Å« ¸ÅÃâ Á¡À¯À²·Î ½ÃÀåÀ» ÁÖµµÇß½À´Ï´Ù. ÀÌ´Â ÀÌ·¯ÇÑ Çö󽺹̵尡 ½±°Ô Á¶ÀÛ ¹× ¼öÁ¤ÇÒ ¼ö ÀÖµµ·Ï ¼³°èµÇ¾î ¿¬±¸ÀÚ°¡ À¯Àü ¹°ÁúÀ» Á¤È®ÇÏ°Ô ¼öÁ¤ÇÒ ¼ö Àֱ⠶§¹®ÀÔ´Ï´Ù. Æ®·£½ºÆå¼Ç ±×·¹ÀÌµå ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È 13.24%ÀÇ CAGR·Î °¡Àå ºü¸£°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • ¿ëµµº°·Î´Â À¯ÀüÀÚ º¯Çü ÀÛ¹° ¹× »ý¹°Ã¼¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ º¹Á¦ ¹× ´Ü¹éÁú ºÎ¹®ÀÌ 2023³â 48.76%ÀÇ °¡Àå Å« ¸ÅÃâ Á¡À¯À²·Î ½ÃÀåÀ» ÁÖµµÇß½À´Ï´Ù. ¶ÇÇÑ, Æ®·£½ºÆä¼Ç ¹× À¯ÀüÀÚ ÆíÁý ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • ÃÖÁ¾ ¿ëµµº°·Î´Â Çмú ¹× ¿¬±¸ ±â°ü ºÎ¹®ÀÌ 2023³â 40.12%ÀÇ ÃÖ´ë ¸ÅÃâ Á¡À¯À²·Î ½ÃÀåÀ» ÁÖµµÇß½À´Ï´Ù. ÀÌ´Â »õ·Î¿î À¯ÀüÀÚ Ä¡·áÁ¦ ¹× À¯ÀüÀÚ Á¶ÀÛ ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö Á¦Ç°À» ½ÃÀå¿¡ Ãâ½ÃÇϱâ À§ÇÑ ¿¬±¸°³¹ß¿¡ Å©°Ô ±â¿©Çϰí Àֱ⠶§¹®ÀÔ´Ï´Ù. ¶ÇÇÑ, À§Å¹ ¿¬±¸ ±â°ü ºÎ¹®Àº ÷´Ü ¿¬±¸ ¹× Á¦Á¶ ±â¼ú¿¡ ´ëÇÑ Ã¤Åðú ÅõÀÚ°¡ Áõ°¡ÇÔ¿¡ µû¶ó ¿¹Ãø ±â°£ µ¿¾È 13.38%ÀÇ CAGR·Î °¡Àå ºü¸£°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • ºÏ¹Ì´Â ¿¬±¸ °³¹ß Ȱµ¿¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡, ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ÷´Ü »ý¸í°øÇÐ ¿¬±¸ ÀÎÇÁ¶ó µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ 2023³â 40.58%ÀÇ °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇÏ¸ç ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Çö󽺹̵å Á¤Á¦ ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

  • ½ÃÀå °èÅë Àü¸Á
    • »óºÎ ½ÃÀå Àü¸Á
    • °ü·Ã/ºÎ¼ö ½ÃÀå Àü¸Á
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • Çö󽺹̵å Á¤Á¦ ½ÃÀå ºÐ¼® Åø
    • ¾÷°è ºÐ¼® - Porter's Five Forces ºÐ¼®
    • PESTEL ºÐ¼®
    • COVID-19ÀÇ ¿µÇ⠺м®

Á¦4Àå Çö󽺹̵å Á¤Á¦ ½ÃÀå : Á¦Ç° ¹× ¼­ºñ½ºº° ÃßÁ¤¡¤µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ Çö󽺹̵å Á¤Á¦ ½ÃÀå Á¦Ç° ¹× ¼­ºñ½ºº° º¯µ¿ ºÐ¼®
  • ¼¼°èÀÇ Çö󽺹̵å Á¤Á¦ ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, Á¦Ç° ¹× ¼­ºñ½ºº°, 2018-2030³â
  • Á¦Ç°
  • ¼­ºñ½º

Á¦5Àå Çö󽺹̵å Á¤Á¦ ½ÃÀå : µî±Þº° ÃßÁ¤¡¤µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ Çö󽺹̵å Á¤Á¦ ½ÃÀå º¯µ¿ ºÐ¼®
  • ¼¼°èÀÇ Çö󽺹̵å Á¤Á¦ ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, µî±Þº°, 2018-2030³â
  • ºÐÀÚ µî±Þ
  • Æ®·£½ºÆå¼Ç µî±Þ

Á¦6Àå Çö󽺹̵å Á¤Á¦ ½ÃÀå : ¿ëµµº° ÃßÁ¤¡¤µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ Çö󽺹̵å Á¤Á¦ ½ÃÀå ¿ëµµº° º¯µ¿ ºÐ¼®
  • ¼¼°èÀÇ Çö󽺹̵å Á¤Á¦ ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, ¿ëµµº°, 2018-2030³â
  • Ŭ·Î´×°ú ´Ü¹éÁú ¹ßÇö
    • ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
  • Æ®·£½ºÆå¼Ç°ú À¯ÀüÀÚ ÆíÁý
    • ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
  • ±âŸ
    • ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â

Á¦7Àå Çö󽺹̵å Á¤Á¦ ½ÃÀå : ÃÖÁ¾ ¿ëµµº° ÃßÁ¤¡¤µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ Çö󽺹̵å Á¤Á¦ ½ÃÀå ÃÖÁ¾ ¿ëµµº° º¯µ¿ ºÐ¼®
  • ¼¼°èÀÇ Çö󽺹̵å Á¤Á¦ ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, ÃÖÁ¾ ¿ëµµº°, 2018-2030³â
  • Á¦¾à¡¤¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
  • Çмú¿¬±¸±â°ü
  • ¼öŹ¿¬±¸±â°ü

Á¦8Àå Çö󽺹̵å Á¤Á¦ ½ÃÀå : Áö¿ªº° ÃßÁ¤¡¤µ¿Ç⠺м®

  • Áö¿ªº° ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â ¹× 2030³â
  • Áö¿ª ½ÃÀå ´ë½Ãº¸µå
  • ºÏ¹Ì
    • ºÏ¹Ì ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • À¯·´ ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ³ë¸£¿þÀÌ
    • ½º¿þµ§
    • µ§¸¶Å©
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ű¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ¶óƾ¾Æ¸Þ¸®Ä« ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • Äí¿þÀÌÆ®

Á¦9Àå °æÀï »óȲ

  • ±â¾÷/°æÀï ºÐ·ù
  • Àü·« ¸ÅÇÎ
  • ±â¾÷ ½ÃÀå »óȲ ºÐ¼®, 2023³â
  • ±â¾÷ °³¿ä/»óÀå ±â¾÷
    • Merck KGaA
    • QIAGEN
    • Thermo Fisher Scientific, Inc.
    • Takara Bio
    • Promega Corporation
    • Zymo Research
    • MP BIOMEDICALS
    • New England Biolabs
    • MCLAB
    • Applied Biological Materials, Inc.
ksm 24.09.24

Plasmid Purification Market Growth & Trends:

The global plasmid purification market size is anticipated to reach USD 3.69 billion by 2030 and is projected to grow at a CAGR of 11.60% from 2024 to 2030, according to a new report by Grand View Research, Inc. Rising acceptance of cell & gene therapy and growing demand for recombinant technology products are factors contributing to market growth. Moreover, technological advancements in plasmid purification further propel market growth.

Plasmids are crucial in gene therapy and genetic medicine. Their unique properties allow them to serve as effective vectors for delivering therapeutic genes into target cells. Plasmids function by introducing exogenous genes into specific cells to correct or replace defective genes responsible for diseases. Moreover, with the increasing acceptance and application of gene therapy for treating various diseases, there is a growing need for purified plasmid DNA. In gene therapy, plasmids serve as vectors for delivering therapeutic genes.

Researchers design plasmids to carry therapeutic genes, including normal copies of mutated genes, genes encoding proteins to combat disease, or RNA molecules like shRNA that can silence harmful genes. Plasmid purification is critical in the development and application of gene therapy. Contaminants such as chromosomal DNA, proteins, endotoxins, and residual bacterial components can interfere with the efficacy and safety of the therapeutic product. Thus, advancements in purification technologies enhance the yield and quality of plasmid DNA, facilitating the scalability of plasmid production, which is essential for meeting the increasing demands of gene therapy development.

The COVID-19 pandemic has significantly impacted the market growth. The increased demand for synthetic biology products, driven by the urgent need for COVID-19 vaccines and treatments, has accelerated research and development (R&D) in cloning technology. This surge in R&D activities in synthetic biology has led to increased funding and investment in companies involved in vaccine development, diagnostics, and therapeutic research. Moreover, despite the challenges posed by the pandemic, the market is expected to continue growing steadily due to the increasing adoption of novel technologies, the rising demand for gene therapies, and ongoing advancements in genetic engineering.

However, one of the primary concerns of the market is the ethical constraints related to the use of recombinant DNA technology is the misuse of gene cloning and synthesis technology in the creation of harmful pathogens through synthetic biology techniques to develop bioweapons. Improper handling or disposal of synthetic DNA and plasmids could lead to environmental contamination. Engineered organisms released into the environment could have ecological consequences.

Plasmid Purification Market Report Highlights:

  • The products segment led the market with the largest revenue share of 72.93% in 2023, as the use of specialized kits and reagents significantly enhances the efficiency, reliability, and quality of the purification process. Furthermore, the services segment is anticipated to experience at a significant CAGR of 12.58% from 2024 to 2030
  • Based on grade, the molecular grade segment led the market with the largest revenue share of 58.42% in 2023, as these plasmids are engineered to be easily manipulated and modified, allowing researchers to make precise changes to the genetic material. The transfection grade segment is anticipated to grow at the fastest CAGR of 13.24% over the forecast period
  • Based on application, the cloning & protein segment led the market with the largest revenue share of 48.76% in 2023, owing to the growing demand for genetically modified crops and organisms. Furthermore, the transfection & gene editing segment is expected to grow at the fastest CAGR over the forecast period.
  • Based on end use, the academic & research institutes segment led the market with the largest revenue share of 40.12% in 2023, driven by their significant contribution to R&D to bring novel gene therapy treatments and engineered biotechnological products to market. Also, the contract research organizations segment is expected to expand at the fastest CAGR of 13.38% during the forecast period, due to their increasing adoption and investment in advanced research and manufacturing technologies
  • North America dominated the market with the largest revenue share of 40.58% in 2023, owing to factors such as increasing investments in R&D activities, rising demand for personalized medicine, and advanced biotechnology research infrastructure

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
    • 1.2.1. Product & Service Segment
    • 1.2.2. Grade Segment
    • 1.2.3. Application Segment
    • 1.2.4. End Use Segment
  • 1.3. Information Analysis
    • 1.3.1. Market formulation & data visualization
  • 1.4. Data Validation & Publishing
  • 1.5. Information Procurement
    • 1.5.1. Primary Research
  • 1.6. Information or Data Analysis
  • 1.7. Market Formulation & Validation
  • 1.8. Market Model
  • 1.9. Total Market: CAGR Calculation
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Plasmid Purification Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Growing demand for recombinant DNA technology (rDNA) products
      • 3.2.1.2. Technological advancements in plasmid purification
      • 3.2.1.3. Increasing adoption of cell and gene therapies
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Ethical constraints related to the use of rDNA technology
  • 3.3. Plasmid Purification Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Plasmid Purification Market: Product & Service Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Plasmid Purification Market Product & Service Movement Analysis
  • 4.3. Global Plasmid Purification Market Size & Trend Analysis, by Product & Service, 2018 to 2030 (USD Million)
  • 4.4. Products
    • 4.4.1. Products market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.2. Instruments
      • 4.4.2.1. Instruments market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.3. Kits & Reagents
      • 4.4.3.1. Kits & reagents market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Services
    • 4.5.1. Services market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Plasmid Purification Market: Grade Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Plasmid Purification Market Grade Movement Analysis
  • 5.3. Global Plasmid Purification Market Size & Trend Analysis, by Grade, 2018 to 2030 (USD Million)
  • 5.4. Molecular Grade
    • 5.4.1. Molecular-grade market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Transfection Grade
    • 5.5.1. Transfection grade market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Plasmid Purification Market: Application Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Plasmid Purification Market Application Movement Analysis
  • 6.3. Global Plasmid Purification Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 6.4. Cloning & Protein Expression
    • 6.4.1. Cloning & protein expression market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.5. Transfection & Gene Editing
    • 6.5.1. Transfection & gene editing market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Plasmid Purification Market: End Use Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Global Plasmid Purification Market End Use Movement Analysis
  • 7.3. Global Plasmid Purification Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 7.4. Pharmaceutical & Biotechnology Companies
    • 7.4.1. Pharmaceutical & biotechnology companies market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5. Academic & Research Institutes
    • 7.5.1. Academic & research institutes market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6. Contract Research Organizations
    • 7.6.1. Contract research organizations market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Plasmid Purification Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2023 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. North America
    • 8.3.1. North America market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.3.2. U.S.
      • 8.3.2.1. Key country dynamics
      • 8.3.2.2. Competitive scenario
      • 8.3.2.3. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.3.3. Canada
      • 8.3.3.1. Key country dynamics
      • 8.3.3.2. Competitive scenario
      • 8.3.3.3. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.3.4. Mexico
      • 8.3.4.1. Key country dynamics
      • 8.3.4.2. Competitive scenario
      • 8.3.4.3. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4. Europe
    • 8.4.1. Europe market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.4.2. UK
      • 8.4.2.1. Key country dynamics
      • 8.4.2.2. Competitive scenario
      • 8.4.2.3. UK market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.4.3. Germany
      • 8.4.3.1. Key country dynamics
      • 8.4.3.2. Competitive scenario
      • 8.4.3.3. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.4.4. France
      • 8.4.4.1. Key country dynamics
      • 8.4.4.2. Competitive scenario
      • 8.4.4.3. France market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.4.5. Italy
      • 8.4.5.1. Key country dynamics
      • 8.4.5.2. Competitive scenario
      • 8.4.5.3. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.4.6. Spain
      • 8.4.6.1. Key country dynamics
      • 8.4.6.2. Competitive scenario
      • 8.4.6.3. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.4.7. Norway
      • 8.4.7.1. Key country dynamics
      • 8.4.7.2. Competitive scenario
      • 8.4.7.3. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.4.8. Sweden
      • 8.4.8.1. Key country dynamics
      • 8.4.8.2. Competitive scenario
      • 8.4.8.3. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.4.9. Denmark
      • 8.4.9.1. Key country dynamics
      • 8.4.9.2. Competitive scenario
      • 8.4.9.3. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.5. Asia Pacific
    • 8.5.1. Asia Pacific market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.5.2. Japan
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Competitive scenario
      • 8.5.2.3. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.5.3. China
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Competitive scenario
      • 8.5.3.3. China market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.5.4. India
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Competitive scenario
      • 8.5.4.3. India market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.5.5. Australia
      • 8.5.5.1. Key country dynamics
      • 8.5.5.2. Competitive scenario
      • 8.5.5.3. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.5.6. South Korea
      • 8.5.6.1. Key country dynamics
      • 8.5.6.2. Competitive scenario
      • 8.5.6.3. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.5.7. Thailand
      • 8.5.7.1. Key country dynamics
      • 8.5.7.2. Competitive scenario
      • 8.5.7.3. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.6. Latin America
    • 8.6.1. Latin America market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.6.2. Brazil
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Competitive scenario
      • 8.6.2.3. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.6.3. Argentina
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Competitive scenario
      • 8.6.3.3. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.7. MEA
    • 8.7.1. MEA market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.7.2. South Africa
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Competitive scenario
      • 8.7.2.3. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.7.3. Saudi Arabia
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Competitive scenario
      • 8.7.3.3. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.7.4. UAE
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Competitive scenario
      • 8.7.4.3. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.7.5. Kuwait
      • 8.7.5.1. Key country dynamics
      • 8.7.5.2. Competitive scenario
      • 8.7.5.3. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company/Competition Categorization
  • 9.2. Strategy Mapping
  • 9.3. Company Market Position Analysis, 2023
  • 9.4. Company Profiles/Listing
    • 9.4.1. Merck KGaA
      • 9.4.1.1. Company overview
      • 9.4.1.2. Financial performance
      • 9.4.1.3. Product/Service benchmarking
      • 9.4.1.4. Strategic initiatives
    • 9.4.2. QIAGEN
      • 9.4.2.1. Company overview
      • 9.4.2.2. Financial performance
      • 9.4.2.3. Product/Service benchmarking
      • 9.4.2.4. Strategic initiatives
    • 9.4.3. Thermo Fisher Scientific, Inc.
      • 9.4.3.1. Company overview
      • 9.4.3.2. Financial performance
      • 9.4.3.3. Product/Service benchmarking
      • 9.4.3.4. Strategic initiatives
    • 9.4.4. Takara Bio
      • 9.4.4.1. Company overview
      • 9.4.4.2. Financial performance
      • 9.4.4.3. Product/Service benchmarking
      • 9.4.4.4. Strategic initiatives
    • 9.4.5. Promega Corporation
      • 9.4.5.1. Company overview
      • 9.4.5.2. Financial performance
      • 9.4.5.3. Product/Service benchmarking
      • 9.4.5.4. Strategic initiatives
    • 9.4.6. Zymo Research
      • 9.4.6.1. Company overview
      • 9.4.6.2. Financial performance
      • 9.4.6.3. Product/Service benchmarking
      • 9.4.6.4. Strategic initiatives
    • 9.4.7. MP BIOMEDICALS
      • 9.4.7.1. Company overview
      • 9.4.7.2. Financial performance
      • 9.4.7.3. Product/Service benchmarking
      • 9.4.7.4. Strategic initiatives
    • 9.4.8. New England Biolabs
      • 9.4.8.1. Company overview
      • 9.4.8.2. Financial performance
      • 9.4.8.3. Product/Service benchmarking
      • 9.4.8.4. Strategic initiatives
    • 9.4.9. MCLAB
      • 9.4.9.1. Company overview
      • 9.4.9.2. Financial performance
      • 9.4.9.3. Product/Service benchmarking
      • 9.4.9.4. Strategic initiatives
    • 9.4.10. Applied Biological Materials, Inc.
      • 9.4.10.1. Company overview
      • 9.4.10.2. Financial performance
      • 9.4.10.3. Product/Service benchmarking
      • 9.4.10.4. Strategic initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦